Thomas E Lloyd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9458417/publications.pdf

Version: 2024-02-01

90 papers

6,777 citations

71061 41 h-index 78 g-index

98 all docs 98 docs citations

98 times ranked

8487 citing authors

#	Article	IF	CITATIONS
1	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. Clinical Infectious Diseases, 2022, 74, 427-436.	2.9	15
2	Prevalence of avascular necrosis in idiopathic inflammatory myopathies: a single-centre experience. Rheumatology, 2022, 61, 936-942.	0.9	2
3	<scp>Antiâ€Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	2.9	6
4	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With <scp>Myositis‧pecific</scp> Autoantibodies. Arthritis and Rheumatology, 2022, 74, 508-517.	2.9	24
5	Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis. Annals of Neurology, 2022, 91, 317-328.	2.8	9
6	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Science Translational Medicine, 2022, 14, eabi9196.	5.8	27
7	Human pluripotent stem cell-derived myogenic progenitors undergo maturation to quiescent satellite cells upon engraftment. Cell Stem Cell, 2022, 29, 610-619.e5.	5.2	10
8	Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nature Communications, 2022, 13, 2306.	5.8	20
9	p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). Cell, 2021, 184, 689-708.e20.	13.5	104
10	UPF1 reduces C9orf72 HRE-induced neurotoxicity in the absence of nonsense-mediated decay dysfunction. Cell Reports, 2021, 34, 108925.	2.9	14
11	Neuropathy-causing TRPV4 mutations disrupt TRPV4-RhoA interactions and impair neurite extension. Nature Communications, 2021, 12, 1444.	5.8	25
12	Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1186-1196.	0.9	9
13	The phenotype of myositis patients with anti-Ku autoantibodies. Seminars in Arthritis and Rheumatism, 2021, 51, 728-734.	1.6	13
14	An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. IScience, 2021, 24, 103221.	1.9	27
15	Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nature Neuroscience, 2021, 24, 1673-1685.	7.1	38
16	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2021, 39, 351-356.	0.4	2
17	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2021, 39, 351-356.	0.4	8
18	Secondary Causes of Myositis. Current Treatment Options in Neurology, 2020, 22, 38.	0.7	5

#	Article	IF	CITATIONS
19	Assessing non-Mendelian inheritance in inherited axonopathies. Genetics in Medicine, 2020, 22, 2114-2119.	1.1	15
20	Ultra-efficient sequencing of T Cell receptor repertoires reveals shared responses in muscle from patients with Myositis. EBioMedicine, 2020, 59, 102972.	2.7	11
21	TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca2+. Nature Communications, 2020, 11, 2679.	5.8	45
22	Teleneurology during the COVID-19 pandemic: A step forward in modernizing medical care. Journal of the Neurological Sciences, 2020, 414, 116930.	0.3	67
23	Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Annals of the Rheumatic Diseases, 2020, 79, 1234-1242.	0.5	80
24	Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain, 2020, 143, 3589-3602.	3.7	39
25	TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. ELife, 2020, 9, .	2.8	48
26	Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. Muscle and Nerve, 2019, 59, 70-75.	1.0	12
27	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	4.9	91
28	How can an understanding of the C9orf72 gene translate into amyotrophic lateral sclerosis therapies?. Expert Review of Neurotherapeutics, 2019, 19, 895-897.	1.4	1
29	Identification of distinctive interferon gene signatures in different types of myositis. Neurology, 2019, 93, e1193-e1204.	1.5	115
30	Variation in <i>SIPA1L2</i> is correlated with phenotype modification in Charcot– Marie– Tooth disease type 1A. Annals of Neurology, 2019, 85, 316-330.	2.8	33
31	Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study. Journal of Neuromuscular Diseases, 2019, 6, 201-211.	1.1	19
32	Myositis Autoantigen Expression Correlates With Muscle Regeneration but Not Autoantibody Specificity. Arthritis and Rheumatology, 2019, 71, 1371-1376.	2.9	29
33	Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice. Journal of Visualized Experiments, 2019, , .	0.2	2
34	Heterogeneity in gut microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity. Journal of Nutritional Biochemistry, 2019, 64, 170-181.	1.9	52
35	New Developments in the Genetics of Inclusion Body Myositis. Current Rheumatology Reports, 2018, 20, 26.	2.1	17
36	Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell, 2018, 173, 958-971.e17.	13.5	303

#	Article	lF	CITATIONS
37	FUS causes synaptic hyperexcitability in Drosophila dendritic arborization neurons. Brain Research, 2018, 1693, 55-66.	1.1	16
38	Fifteenâ€year longitudinal followâ€up of a patient with severe earlyâ€onset Charcotâ€Marieâ€Tooth disease type 2A. Muscle and Nerve, 2018, 57, E126-E128.	1.0	0
39	TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature, 2018, 563, 508-513.	13.7	163
40	Drosophila models of amyotrophic lateral sclerosis with defects in RNA metabolism. Brain Research, 2018, 1693, 109-120.	1.1	14
41	Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology, 2017, 88, 1454-1460.	1.5	39
42	Tdp-43 cryptic exons are highly variable between cell types. Molecular Neurodegeneration, 2017, 12, 13.	4.4	63
43	Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Annals of the Rheumatic Diseases, 2017, 76, 681-687.	0.5	132
44	More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology, 2017, 56, kew470.	0.9	67
45	Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron, 2017, 94, 93-107.e6.	3.8	274
46	Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. Acta Neuropathologica Communications, 2017, 5, 24.	2.4	50
47	Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Annals of Neurology, 2017, 81, 227-239.	2.8	59
48	Internal grant review to increase grant funding for junior investigators. Annals of Neurology, 2017, 82, 497-502.	2.8	4
49	Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respiratory Medicine, 2017, 130, 52-54.	1.3	22
50	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. Journal of Neuromuscular Diseases, 2016, 3, 67-75.	1.1	44
51	A Case of Morvan Syndrome Mimicking Amyotrophic Lateral Sclerosis With Frontotemporal Dementia. Journal of Clinical Neuromuscular Disease, 2016, 17, 207-211.	0.3	6
52	Statin-Induced Anti-HMGCR-Associated Myopathy. Journal of the American College of Cardiology, 2016, 68, 234-235.	1.2	44
53	FIG4 regulates lysosome membrane homeostasis independent of phosphatase function. Human Molecular Genetics, 2016, 25, 681-692.	1.4	46
54	Nucleocytoplasmic transport in <i>C9orf72-</i> mediated ALS/FTD. Nucleus, 2016, 7, 132-137.	0.6	27

#	Article	lF	Citations
55	Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. Journal of Magnetic Resonance Imaging, 2016, 44, 1513-1521.	1.9	34
56	Cytosolic 5′â€Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care and Research, 2016, 68, 66-71.	1.5	89
57	Spectrum of Muscle Histopathologic Findings in Fortyâ€Two Scleroderma Patients With Weakness. Arthritis Care and Research, 2015, 67, 1416-1425.	1.5	56
58	Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e172.	3.1	38
59	Genotype–phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the <i>MPZ</i> pene. Brain, 2015, 138, 3180-3192.	3.7	80
60	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature, 2015, 525, 56-61.	13.7	835
61	Drosophila models of neurologic disease. Experimental Neurology, 2015, 274, 1-3.	2.0	5
62	Laing distal myopathy pathologically resembling inclusion body myositis. Annals of Clinical and Translational Neurology, 2014, 1, 1053-1058.	1.7	10
63	A TRPV Channel in Drosophila Motor Neurons Regulates Presynaptic Resting Ca2+ Levels, Synapse Growth, and Synaptic Transmission. Neuron, 2014, 84, 764-777.	3.8	68
64	WIDE AWAKE Mediates the Circadian Timing of Sleep Onset. Neuron, 2014, 82, 151-166.	3.8	128
65	Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology, 2014, 83, 426-433.	1.5	192
66	Synaptotagmin 2 Mutations Cause an Autosomal-Dominant Form of Lambert-Eaton Myasthenic Syndrome and Nonprogressive Motor Neuropathy. American Journal of Human Genetics, 2014, 95, 332-339.	2.6	96
67	Peripheral Neuropathy. Neuroimaging Clinics of North America, 2014, 24, 49-65.	0.5	122
68	The ALS gene FUS regulates synaptic transmission at the Drosophila neuromuscular junction. Human Molecular Genetics, 2014, 23, 3810-3822.	1.4	42
69	Hereditary Channelopathies Caused by TRPV4 Mutations. , 2014, , 413-440.		1
70	Top $3\hat{l}^2$ is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. Nature Neuroscience, 2013, 16, 1238-1247.	7.1	124
71	Cbl-associated protein regulates assembly and function of two tension-sensing structures in <i>Drosophila</i> . Development (Cambridge), 2013, 140, 627-638.	1.2	31
72	Increased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl oenzyme A reductase–associated autoimmune myopathy. Arthritis Care and Research, 2012, 64, 1233-1237.	1.5	126

#	Article	IF	Citations
73	Antibody levels correlate with creatine kinase levels and strength in anti–3â€hydroxyâ€3â€methylglutarylâ€coenzyme A reductase–associated autoimmune myopathy. Arthritis a Rheumatism, 2012, 64, 4087-4093.	and7	201
74	The p150Glued CAP-Gly Domain Regulates Initiation of Retrograde Transport at Synaptic Termini. Neuron, 2012, 74, 344-360.	3.8	126
7 5	Neuropeptide Delivery to Synapses by Long-Range Vesicle Circulation and Sporadic Capture. Cell, 2012, 148, 1029-1038.	13.5	137
76	Axonal transport disruption in peripheral nerve disease. Journal of the Peripheral Nervous System, 2012, 17, 46-51.	1.4	6
77	Sciatic nerve tumor and tumor-like lesions—uncommon pathologies. Skeletal Radiology, 2012, 41, 763-774.	1.2	55
78	Treatment and Management of Hereditary Neuropathies., 2011,, 191-213.		2
79	A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Human Molecular Genetics, 2011, 20, 2510-2523.	1.4	177
80	Novel therapeutic approaches for inclusion body myositis. Current Opinion in Rheumatology, 2010, 22, 658-664.	2.0	15
81	Flightless flies: <i>Drosophila</i> models of neuromuscular disease. Annals of the New York Academy of Sciences, 2010, 1184, e1-20.	1.8	120
82	When cell biology meets development: endocytic regulation of signaling pathways. Genes and Development, 2002, 16, 1314-1336.	2.7	194
83	Hrs Regulates Endosome Membrane Invagination and Tyrosine Kinase Receptor Signaling in Drosophila. Cell, 2002, 108, 261-269.	13.5	412
84	Endophilin Mutations Block Clathrin-Mediated Endocytosis but Not Neurotransmitter Release. Cell, 2002, 109, 101-112.	13.5	305
85	pRIMing synaptic vesicles for fusion. Nature Neuroscience, 2001, 4, 965-966.	7.1	5
86	Targeted Mutations in the Syntaxin H3 Domain Specifically Disrupt SNARE Complex Function in Synaptic Transmission. Journal of Neuroscience, 2001, 21, 9142-9150.	1.7	47
87	The ROP-Syntaxin interaction inhibits neurotransmitter release. European Journal of Cell Biology, 2001, 80, 196-199.	1.6	17
88	A Genome-Wide Search for Synaptic Vesicle Cycle Proteins in Drosophila. Neuron, 2000, 26, 45-50.	3.8	105
89	Crystal Structure of the VHS and FYVE Tandem Domains of Hrs, a Protein Involved in Membrane Trafficking and Signal Transduction. Cell, 2000, 100, 447-456.	13.5	175
90	Syntaxin 1A Interacts with Multiple Exocytic Proteins to Regulate Neurotransmitter Release In Vivo. Neuron, 1999, 23, 593-605.	3.8	189